arrow
T

Ton N. Schumacher

Netherlands Cancer Institute
H指数:109
被引数:8.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC

肿瘤微环境的时空组成可预测转移性TNBC对免疫检查点抑制的反应

2026-02-180
PRE
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy

Neo-stim推进个性化新抗原特异性过继性T细胞治疗

2026-02-050
OAAI
Guidelines for T cell nomenclature

T细胞命名指南

2025-11-180
OAAI
In Remembrance of Professor Zelig Eshhar: A Life Committed to CAR-T

缅怀泽利格·埃什哈教授:一位致力于CAR-T的一生

2025-11-010
PRE
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers

错配修复功能 proficient 结直肠癌的新辅助免疫疗法

Nature
IF48.5
2025-10-200
PRE
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial

新辅助伊匹木单抗和纳武利尤单抗在可切除皮肤鳞状细胞癌中的应用:一项随机Ⅱ期临床试验

2025-10-080
OAAI
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma

III期黑色素瘤患者尽管对术前ipiLimumab联合nivolumab治疗表现出病理学反应,但疾病仍复发时的临床、病理及分子特征

2025-09-300
OA
Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies

基于从诊断性肿瘤活检样本高通量TCR发现,实现下一代工程化TCR-T疗法

2025-01-140
OA
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

新辅助nivolumab或nivolumab联合ipilimumab治疗早期三阴性乳腺癌: 2期适应性试验

2024-09-162
OAAI
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
2024-09-150
OAAI
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

局部晚期MMR-deficient结肠癌的新辅助免疫疗法:NICHE-2研究3年无病生存率

2024-09-013
PRE
Neoadjuvant nivolumab/relatlimab or nivolumab/ ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)

新辅助尼沃鲁单抗/瑞拉利单抗或尼沃鲁单抗/伊匹木单抗在肿瘤浸润淋巴细胞(TILs)较高的三阴性乳腺癌中的应用

2024-09-010
PRE
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer
2024-06-0634
PRE